Open-label extension
A follow-on study where trial participants keep taking the drug with everyone knowing it — useful for safety data, weak for proving long-term benefit.
Most of what labels say about long-term use comes from these. know their shape before you weigh their sentences.
What it is
After a placebo-controlled trial ends, participants are often invited to continue open-label: everyone gets the drug, everyone knows it, sometimes for years. These studies supply most long-term safety data.
The structural weakness
Without placebo or blinding, an extension cannot separate drug effect from time, expectation, or dropout — people who feel worse leave, so the remaining population is self-selected for tolerating and liking the drug. 'Patients maintained improvement in a 52-week open-label extension' is evidence of something, but much less than it sounds like.
Somewhere to put it
free. anonymous. people who’ve been where you are 🤍
get veisund — it’s freewant the deeper story? read prescribed to fail
Questions
Are open-label results worthless?
No — they are real safety surveillance and honest signals of tolerability. They are weak specifically for proving continued benefit versus no drug.
What should I ask about a long-term claim?
What kind of study it came from. Blinded and controlled beats open-label; open-label beats nothing; knowing which you are reading beats both.
Keep reading
More from the glossary
veisund is not a clinical product and does not diagnose, treat, or cure any condition. if you’re in crisis, call or text 988 (u.s.), 24/7, free.